Aristotle University Of Thessaloniki (AUTH)
Τα όρια εφαρμογής του άρθρου 102 ΣΛΕΕ στην αγορά του φαρμάκου και η επίπτωσή του στις παράλληλες εξαγωγές
Abstract
dc:descriptionThe aim of this study is to present the case of abuse of dominant position in the market for pharmaceuticals, taking into account the particularities of this market and analysing relative case law examples, with an emphasis on the Glaxo case ( C-468/06-478/06). The study attempts to analyse the application of article 102 TFEU in the market for pharmaceuticals, without by-passing other parts of internal market legislation of the EU, and having as yardsticks the interest of the consumer-patient and the safeguarding of public health. A crucial aspect of the study, is the analysis of the limits of application of article 102, within the framework defined on the one hand by the interests of the pharmaceutical companies and on the other by the need for a smooth operation of the market in the interest of the consumer. These limits are analysed taking into account the sui generis nature of a market shaped to a great extend on the one hand by states and social security institutions, and on the other by the needs of research and development of the pharmaceutical companies. The first part of the study, analyses the market for pharmaceuticals so as to identify the particularities of the market. Research and innovation play a crucial role in this market, with the pharmaceuticals sector showing one of the highest investment indices in Europe. Intellectual property rights are a basic prerequisite for the promotion of innovation. The role of the state and social security institutions is decisive in the pharmaceuticals market, with the need to reduce public spending running counter to the need of social security institutions to cover their costs. The study also addresses the issue of the abuse of dominant position and parallel trade in the pharmaceuticals market. This part of the market witnesses conflicts of interests between the pharmaceutical industry and wholesalers/distributors, as well as between importing and exporting countries, with arguments pro and against each side. The most important of the many particularities of the pharmaceuticals market in the EU is the price setting of pharmaceuticals by member states. The setting of different prices for same products by the member states, while at the same time state institutions are the largest buyers of pharmaceutical products, raises doubts regarding the efficiency of parallel trade. Secondly, even the distribution of pharmaceutical products is regulated by the member states, which issue licences to pharmaceuticals wholesalers, creating additional obligations to both pharmaceutical industries and wholesalers. Thirdly, the latter have the obligation for reasons of public interest to keep stocks so as to secure availability of pharmaceuticals. Therefore, it is neither a reasonable nor a proportionate measure to oblige pharmaceutical industries to supply wholesalers in a low price country with quantities which the wholesalers will eventually export to a higher price country. Nevertheless, the ECJ makes it clear that despite these particularities it considers the parallel trade in pharmaceuticals a right deriving directly from the stipulations of the Convention on the free movement of goods, attempting simultaneously to reconcile this right with the legislation on the protection of intellectual and industrial property. The landmark decision, which brought all the above mentioned issues to the fore and led to a clarification of the views of the Commission as well as the ECJ, was the Syfait and Lelos decision.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Amanatidou, Sevasti
- Αμανατίδου, Σεβαστή
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/37480